Impact of PD-L1 Status on the Development of Cutaneous Immune-Related Adverse Events in Non-Small-Cell Lung Cancer Patients Receiving Immunotherapy
{{output}}
Background: Cutaneous adverse events (cAEs) are among the most frequent immune-related toxicities associated with immune checkpoint inhibitors (ICIs). Previous clinical trials have reported higher rates of dermatologic toxicity with anti-CTLA-4 agents compared... ...
